Novartis' (NVS) PKC412 NDA Granted FDA Priority Review as AML Treatment
Tweet Send to a Friend
Novartis (NYSE: NVS) announced that the US Food and Drug Administration (FDA) granted Priority Review to the PKC412 (midostaurin) new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
